Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Status:
Completed
Trial end date:
2019-06-14
Target enrollment:
Participant gender:
Summary
A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future
health of the mother. GDM is often the culmination of years of unrecognized and unmodified
diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy.
Systematic reviews of older studies conclude that 35-60% women with gestational diabetes will
develop type 2 diabetes (DM2) at rates much greater than control groups who did not have
glucose intolerance during pregnancy. Liraglutide may potentially delay disease progression
in GDM considering the beta -(ß-)cell function improvement in DM2 and ß-cell mass shown to
increase in animal models. This study will examine if the addition of liraglutide to
metformin therapy is more effective than metformin alone in improving insulin sensitivity and
normalizing insulin secretion in at-risk overweight/obese women with prior GDM.